SCHEMBL19084689

SCHEMBL19084689

Cc1nn2c(=O)cc(-c3ccc([N+](=O)[O-])cc3)[nH]c2c1Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSD A5PKW4 8/20 0.52
MAPT P10636 4/20 0.42
MCL1 Q07820 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
LMNA P02545 2/20 0.41
ARF6 P62330 1/20 0.41
SLC27A2 O14975 1/20 0.41
TP53 P04637 1/20 0.39
HTT P42858 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
ENPP1 P22413 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13516190 0.91 KMT2A (0.42) PSDMAPTALDH1A1MEN1KMT2A
SCHEMBL13562088 0.86 KMT2A (0.41) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL13516359 0.85 PSD (0.48) PSDMAPTMCL1ALDH1A1MEN1
SCHEMBL13562095 0.84 AVPR2 (0.41) PSDALDH1A1MEN1KMT2ARAB9A
SCHEMBL13516125 0.83 PTGDR2 (0.42) PSDMAPTKMT2ANPC1RAB9A
SCHEMBL13516051 0.82 CHEK2 (0.43) PSDKMT2A
SCHEMBL13516118 0.82 P2RX3 (0.43) MAPTALDH1A1POLBLMNAADORA2A
SCHEMBL13516019 0.81 AR (0.44) PSDMAPTMEN1KMT2ARAB9A
SCHEMBL19084608 0.81 PSD (0.48) PSDMAPTMCL1ALDH1A1MEN1
SCHEMBL13516380 0.80 KMT2A (0.43) MAPTALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof NAVIGEN, INC. (US) 2020-12-01 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF NAVIGEN, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170189405-A1 ARF6 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF ARF6, ARF1, ARFIP2 PSD 211/4885MAPT 2995/4885MCL1 1775/4885
US-10849901-B2 Arf6 inhibitors and methods of synthesis and use thereof ARF6, ARF1, ARFIP2 PSD 211/4885MAPT 2995/4885MCL1 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.